Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
TRDA
TRDA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
TRDA News
Entrada Therapeutics Grants Restricted Stock Units to New Employees
Mar 02 2026
Newsfilter
Entrada Therapeutics Q4 Earnings Report Analysis
Feb 26 2026
seekingalpha
Entrada Therapeutics CEO Dipal Doshi to Present at 2026 J.P. Morgan Healthcare Conference
Dec 17 2025
Globenewswire
Entrada Therapeutics CEO Dipal Doshi to Present at 2026 J.P. Morgan Healthcare Conference
Dec 17 2025
Newsfilter
Entrada Therapeutics Grants 40,650 RSUs and Options to New Employees
Dec 04 2025
Globenewswire
5AM Venture Sells Its Viking Stake—Wise Decision or Lost Chance?
Nov 18 2025
NASDAQ.COM
5AM Venture Exits MoonLake Following a Challenging Year: Key Highlights to Note
Nov 18 2025
NASDAQ.COM
3 'Strong Buy' Stocks to Consider Now with Potential Upside Exceeding 125%, Analysts Say (10/24/2025)
Oct 24 2025
TipRanks
Entrada (TRDA) Q2 Revenue Drops 98%
Aug 06 2025
NASDAQ.COM
Validea Kenneth Fisher Strategy Daily Upgrade Report - 7/1/2025
Jul 01 2025
NASDAQ.COM
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
Jun 03 2025
Newsfilter
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 02 2025
Newsfilter
Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
May 28 2025
Newsfilter
Validea Kenneth Fisher Strategy Daily Upgrade Report - 5/7/2025
May 07 2025
NASDAQ.COM
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
Mar 24 2025
Newsfilter
FDA Clears Entrada Therapeutics' Early-Stage For Potential Treatment Of Duchenne Muscular Dystrophy
Feb 24 2025
Benzinga
Show More News
